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Abstract Bile acids entering into enterohepatic circulating
are primary acids synthesized from cholesterol in hepatocyte.
They are secreted actively across canalicular membrane and
carried in bile to gallbladder, where they are concentrated
during digestion. About 95 % BAs are actively taken up from
the lumen of terminal ileum efficiently, leaving only
approximately 5 % (or approximately 0.5 g/d) in colon, and a
fraction of bile acids are passively reabsorbed after a series of
modifications in the human large intestine including decon-
jugation and oxidation of hydroxy groups. Bile salts hydro-
lysis and hydroxy group dehydrogenation reactions are
performed by a broad spectrum of intestinal anaerobic bac-
teria. Next, hepatocyte reabsorbs bile acids from sinusoidal
blood, which are carried to liver through portal vein via a
series of transporters. Bile acids (BAs) transporters are critical
for maintenance of the enterohepatic BAs circulation, where
BAs exert their multiple physiological functions including
stimulation of bile flow, intestinal absorption of lipophilic
nutrients, solubilization, and excretion of cholesterol. Tight
regulation of BA transporters via nuclear receptors (NRs) is
necessary to maintain proper BA homeostasis. In conclusion,
disturbances of enterohepatic circulation may account for
pathogenesis of gallstones diseases, including BAs trans-
porters and their regulatory NRs and the metabolism of
intestinal bacterias, etc.
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TNFa Tumor necrosis factor alpha
HNF1a Hepatic nuclear factor 1a
ILBP Ileal lipid binding protein
SULT2A1 Sulfotransferases2A1
UGT2B4 Uridine dipho-sphate glucuronosyltransferase
2 family, polypeptide B4
BACS Bile acid-CoA synthetase
BAT Bile acid-CoA amino acid N-acetyltransferase
CCK Cholecystokinin
FGF Fibroblast growth factor
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Introduction
Gallstone disease is a frequent and economically relevant
health problem worldwide. In Western countries, the mor-
bidity of cholelithiasis is about 10–20 % (Kratzer 1999).
Moreover, between 20 and 40 % of gallstone patients
become symptomatic or develop complications (Gibney
1990), and more than 700,000 people in the US and 170,000
in Germany underwent cholecystectomies annually (Sandler
et al. 2002). Economically, gallstone disease has been
identified as the second most costly disorder of the digestive
tract. A genetic component in the susceptibility to choles-
terol gallstones has been recognized (Zubler et al. 1998).
Bile acid pool size is maintained relatively constant at about
3–5 g in healthy subjects by two mechanisms, enterohepatic
circulation and de novo synthesis of bile acids. This latter
mechanism compensates for the daily facal loss (about
0.2–0.6 g) of bile acids, whereas the majority of the pool is
conserved by the former mechanism (Lanzini and Lanzar-
otto 2000). The term enterohepatic circulation (EHC)
denotes the movement of bile acid molecules from the liver
to the small intestine and back to the liver. Bile acids tra-
verse the hepatocyte and are actively secreted into canalic-
ular bile, completing the enterohepatic cycle. During the
enterohepatic circulation, bile salts encounter populations of
facultative and anaerobic bacteria, which is relatively small
in quantity but rather diversified in the small bowel. Bile salt
metabolized by small bowel microbes consists mainly of
deconjugation and hydroxy group oxidation. Ileal bile salt
transport is highly efficient (about 95 %), but approximately
400–800 mg of bile salts escapes the enterohepatic circula-
tion daily and becomes substrate for significant microbial
biotransforming reactions in the large bowel (Ridlon et al.
2006).
Bile Acid Biotransformation by Bacteria
Bile Salt Hydrolase(s)
The human liver can produce close to 1 L of bile every
day, but comparatively small amounts are lost from the
body. Hence, approximately 95 % of the bile acids dis-
tributed to the duodenum are reabsorbed into venous blood
within the ileum and colon, and subsequently, through
mesenteric vein, they arrive at the portal vein, finally they
approach the sinusoids of the liver. And hepatocytes re-
uptake the bile acids capably from sinusoidal blood, while
small amounts escape into systemic circulation. Bile acids
are resecreted into canaliculi by the hepatocyte afterward.
As a whole, the enterohepatic circulation makes each bile
salt molecule available several times during a solitary
digestive stage. During these processes, an important bio-
transformation that must take place before subsequent
modifications is termed deconjugation (Batta et al. 1990),
catalyzed by the bile salt hydrolase (BSH).
BSH is an enzyme produced by several bacterial species
in the human or animal gastrointestinal tract that catalyzes
the glycine- or taurine-linked bile salt deconjugation
reaction. And it belongs to the choloylglycine hydrolase
enzymes family, which also comprises penicillin amidases.
Both of them have been classified as an N-terminal
nucleophilic (Ntn) hydrolase with an N-terminal cysteine
residue. BSH catalyzes the hydrolysis of amide bond in the
conjugated bile salts (CBS), then forms the deconjugated
bile acid (mainly cholic and quenodeoxycholic) until free
amino acids are dissociated. These primary bile acids may
afterward undergo dehydroxylation and get converted into
secondary bile acids (deoxycholic and lithocholic) after a
series of changes.
BSH has already been identified that its substrate (bile
acids) is either on amino acid groups (glycine/taurine) or
on cholate steroid nucleus. There have been a number of
reports on cholate group identification by BSH. It has been
reported in several literatures that among the BSHs whose
substrate is at amino acid moieties, the hydrolysis of gly-
coconjugated bile salts are usually more efficient than the
tauroconjugated bile salts (Oh et al. 2008; Kim et al. 2004;
Tanaka et al. 2000). A Lactobacillus buchneri JCM1069
exhibited hydrolase activity against the taurodeoxycholic
acid but not against the taurocholic acid, although both
acids had taurine as their amino acid moiety, they varied in
their steroid moieties at 7a position (Moser and Savage
2001).
Some of probiotics with BSH have been recognized and
characterized. Interestingly bile salt tolerance has generally
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been considered more important than that of the other
properties during probiotic selection in Bifidobacterium,
such as gastric and pancreatic tolerance. It has also been
observed that pancreatin supported Bifidobacterium to
survive in the gastrointestinal tract and withstand against
the antimicrobial property of bile acids (Masco et al. 2007).
It is possible that the presence of BSH and some transporter
proteins lead to bile salt tolerance of some microorganisms,
which are functionally related to the response efficiently to
the stress from bile salts (Kim and Lee 2008). Microbial
traits must be well tolerant to bile acid if they are to survive
in the human gut (Dethlefsen and McFall-Ngai 2007).
Jones et al. (2008) hypothesized that BSH facilitates col-
onization by mediating the resistance to the conjugated bile
acids.
BSHs are very specific for certain bile types and they
help bacteria to survive in various bile environments
through their contact with bile. This assumption is sup-
ported by the studies carried out in Lactobacillus planta-
rum WCFS1 that have four BSH genes, and L. acidophilus
NCFM that have two BSH genes (McAuliffe 2005; Bron
et al. 2006). Bile addition may sometimes have inducing or
inhibiting effects on BSHs as they are highly substrate
specific. Researches have shown that the expression of
BSH 1 by the bile was induced sixfold, while that of BSH 3
was reduced fivefold. Two BSH genes of L. acidophilus
NCFM were inactivated, which indicated that the encoded
enzymes possessed different substrate specificities (Bron
et al. 2006). It is also known that different parts of bile
stimulate different BSHs. BSH A activity was stimulated
by the steroid nucleus of bile salts, while the activity of
BSH B was induced by the amino acid side chain
(McAuliffe 2005).
BSH activity has been found mostly in Gram-positive
commensals (except a few Bacteroides), which also acquire
genome homolog, whereas it is lacking in Gram-negative
commensals of the gastrointestinal tract. Escherichia coli
and Salmonella enterica serovar typhimurium are reported
as BSH-negative strains (Begley 2005). The prevalence of
BSH is well recognized among the established probiotic
genera. It is observed foremost in the majority of species
such as genera Lactobacillus (McAuliffe 2005), Bifido-
bacterium (Kim and Lee 2008), Bacteroides (Kawamoto
et al. 1989), and Enterococcus (Franz et al. 2001). Tanaka
et al. (1999) screened more than 300 strains from Bifido-
bacterium, Lactobacillus, Lactococcus lactis, Leuconostoc
mesenteroides, and Streptococcus thermophilus and found
BSH activity in 273 strains in Bifidobacterium and Lacto-
bacillus but missing in L. lactis, L. mesenteroides, and S.
thermophilus. Furthermore, Tannock et al. (1989) conclude
that lactobacilli are the main contributors to total BSH
activity in the murine intestinal tract, according to the fact
that BSH activity in the ileal of these mice was reduced by
86 % in the absence of lactobacilli and by greater than
98 % in the absence of lactobacilli and enterococci com-
pared with samples from control group mice.
Microbial genome analyses have identified homologs
and putative BSH genes recently. It varies from species and
genera in the organization and regulation of genes encod-
ing BSH. Monocistronic BSH genes have been reported in
La. plantarum (Christiaens1992), La. johnsonii (Elkins
et al. 2001), Li. monocytogenes (Dussurget et al. 2002), and
Bi. bifidum (Kim et al. 2004). And the crystal structure
showed that the enzyme encoded by the CBAH-1 gene
forms an active homotetramer (Rossocha et al. 2005).
Polycistronic operons have been characterized that three
genes are involved in bile salt deconjugation (cbsT1,
cbsT2, and cbsHb), which are detected in La. Johnsonii and
La. acidophilus (Elkins et al. 2001). Genes cbsT1 and
cbsT2 appear to be gene duplications that encode tauro-
cholate/CA antiport proteins of the major facilitator
superfamily, however, cbsHb encodes the BSH b-isoform
(Elkins and Savage 2003). BSH expression is also growth
phase-dependent. Stationary phase expression has been
reported in Bacteroides fragilis (Stellwag and Hylemon
1976), and exponential phase expression was reported for
Bi. longum (Tanaka et al. 2000).
Bile Acid Hydroxysteroid Dehydrogenase (HSDH)
The initial step in bile salt transformation is deconjugation
of taurine- and glycine-conjugated bile salts to the
respective unconjugated free bile salts. This process is
mentioned previous. Free bile salts are further processed
via reductive dehydroxylation. Oxidation/reduction of
hydroxy groups at C-3, C-7, and C-12, epimerization of
hydroxyl groups, and 7a/b-dehydroxylation, these pro-
cesses generate the so-called secondary bile salts deoxy-
cholate and lithocholate, which are produced from the
primary bile salts cholate and chenodeoxycholate, respec-
tively. HSDHs are nicotinamide adenine dinucleotide
phosphate (NADPH)-dependent enzymes belonging to the
short-chain dehydrogenase/reductase (SDR) superfamily
(Kavanagh et al. 2008). They catalyze the oxidation/
reduction of hydroxyl groups of neutral steroids, bile acids,
and other steroid derivatives.
Oxidation and epimerization of the 3-, 7-, and 12-
hydroxy groups of bile acids in the GI tract are carried out
by HSDH expressed by intestinal bacteria. Epimerization
of bile acid hydroxy groups is the reversible change in
stereochemistry from a to b configuration with the gener-
ation of a stable oxo-bile acid intermediate. Epimerization
requires the concerted effort of two position-specific,
stereochemically distinct HSDHs of intraspecies or inter-
species origin. For example, the presence of both 7a and
7b-HSDH in C. absonum allows epimerization by a single
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bacterium (Sutherland and Macdonald 1982), whereas
epimerization also can be achieved in cocultures of intes-
tinal bacteria, one possessing 7a-HSDH and the other
7b-HSDH (Hirano and Masuda 1981; MacDonald et al.
1982). The extent of the reversible oxidation and reduction
of bile acid hydroxy groups by HSDH depends in part on
the redox potential of the environment. Addition of oxygen
to the culture medium increases the accumulation of oxo-
bile acids (Sutherland and Macdonald 1982).
3a- and 3b-HSDHs
3a-HSDHs specifically catalyze the reversible, stereospe-
cific oxidation/reduction between 3-oxo-bile acids and
3a-hydroxy bile acids. 3a-HSDHs have been detected in
some of the most prevalent intestinal bacteria, including C.
perfringens (Macdonald et al. 1976), Peptostreptococcus
productus (Edenharder et al. 1989), and Eggerthella lenta
(formerly Eubacterium lentum) (MacDonald et al. 1979,
1977), as well as in intestinal bacteria present in lower
numbers (\105/g wet weight of feces), including C. scin-
dens (Mallonee et al. 1995) and C. hiranonis (Wells and
Hylemon 2000), and in nonintestinal bacteria, including
Pseudomonas testosteroni (Skalhegg 1975). This reversible
process is catalyzed by NAD(P)-dependent enzymes rela-
ted to the short-chain dehydrogenase/reductase superfamily
(Hoffmann and Maser 2007).
3b-HSDHs specifically catalyze the reversible, stereo-
specific oxidation/reduction between 3-oxo-bile acids and
3b-hydroxy bile acids. 3b-HSDHs activities have been
described in species of Clostridium and Rumminococcus.
And 3b-HSDHs have also been proved to preferentially
require NADP(H), with the exception of C. innocuum,
which uses NAD(H) (Edenharder et al. 1989). Dihydroxy
bile acids [deoxycholic acid (DCA), chenodeoxycholic
acid (CDCA), and ursodeoxycholic acid (UDCA)] are
generally better substrates than trihydroxy bile acids
[cholic acid (CA)] (Edenharder et al. 1989; Macdonald
et al. 1983). In fact, three copies of 3a-HSDH genes (the
bile acid-inducible genes baiA1, baiA2, and baiA3) have
been identified from C. scindens (Gopal-Srivastava 1990;
Coleman et al. 1988), and baiA1 has been expressed in
E. coli and characterized (Mallonee et al. 1995).
7a- and 7b-HSDHs
Specifically, 7a-HSDHs and 7b-HSDHs might be utilized
for the selective a/b inversion of the hydroxy group at C-7
of primary bile acids, which is identified at an industrial
level through a multistep chemical process (Iida and
Nishida 1993). Both enzymatic activities have been
detected in many intestinal bacteria (Lepercq et al. 2004).
Genes encoding for 7a-HSDHs have been cloned from
E. coli (Yoshimoto et al. 1991), B. fragilis (Bennett et al.
2003), Clostridium sordellii (Coleman et al. 1994), and
Eubacterium sp (Baron et al. 1991) strains. Moreover, the
crystal structure of the E. coli 7a-HSDH was determined
(Tanaka et al. 1996), and not only the role of active site
residues in catalysis but also the cofactor recognition were
investigated. 7a-HSDHs generally use NADP(H) as a
cofactor, with the exception of E. coli (Prabha and Gupta
1989) and Ba. thetaiotaomicron (Sherrod and Hylemon
1977). C. bifermentans, C. absonum, and Ba. fragilis
7a-HSDHs that use either NAD(H) or NADP(H) as a
cofactor (Macdonald and Sutherland 1983; Hylemon and
Sherrod 1975; Sutherland et al. 1987) On the contrary, less
information is available concerning 7b-HSDHs, enzymes
showing this activity has been partially purified from Ru-
minococcus sp (Akao et al. 1987). and Peptostreptococcus
productus (Edenharder et al. 1989). Recently, the gene
encoding the NADPH-dependent 7b-HSDH from Collin-
sella aerofaciens was identified and cloned (Liu and Aig-
ner 2011).
12a- and 12b-HSDHs
The epimerization of the 12a/b hydroxyl group by micro-
bial cooperation was demonstrated. Previous research
shows that the enzyme catalyses the oxidation of CA
directly to 12-oxochenodeoxycholic acid. Human intestinal
flora exist cooperating microorganisms such as Clostridium
group P strain C 48-50, expressing NADP(H)-dependent
12a-hydroxysteroid dehydrogenase (HSDH) (Macdonald
et al. 1979), and Clostridium paraputrijiicum, strain D
762-06, containing a described NADP(H)-dependent 12P-
HSDH (Edenharder and Pfutzner 1988). NADP-dependent
12a-HSDHs have been detected in Bifidobacterium species
(Aries 1970) and C. leptum (Harris and Hylemon 1978) in
Clostridium group P (Macdonald et al. 1979), whereas
NAD-dependent 12a-HSDH activity was reported in Eg.
lentum (MacDonald et al. 1977) and C. perfringens
(Macdonald et al. 1976). Meanwhile 12b-HSDHs have
been detected in C. Tertium, C. Difficile, and C. parapu-
trificum (Edenharder and Pfutzner 1988; Edenharder and
Schneider 1985). So far, Clostridium group P, strain C
48–50, is the only microorganism known to express HSDH
activity at unusually high level, meanwhile in the absence
of other HSDHs (Macdonald et al. 1979). Potentially,
this microorganism is a good source for producing HSDH.
12a/b-HSDHs characterized to date are constitutively
expressed and noninducible, with the exception of the
12b-HSDH from C. paraputrificum, which is induced by
12-oxo-bile acid substrates (Edenharder and Pfutzner
1988). 12a/b-HSDHs generally have higher affinity for
dihydroxy bile acids (DCA) than for trihydroxy bile acids
(CA and iso-CA) and for free versus conjugated bile acids.
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The 12a-HSDH from C. leptum is an exception, demon-
strating higher affinity for CA conjugates than for free CA
(Harris and Hylemon 1978).
7a/b Dehydroxylation of Bile Acid
Owing to the fact that 7-dehydroxylation cannot be
reversed by the host enzymatic machinery, LCA and DCA
tend to accumulate in the BA pool. However, LCA is
3-sulfated and conjugated at C-24 by the liver, resulting in
a derivative that is poorly absorbed from the colonic
mucosa, and consequently LCA is not present in significant
amounts in the bile (Hofmann 2004). Thus major BAs in
human bile are CA, CDCA, and DCA, which are accom-
panied by minor amounts of UDCA, LCA, and other BAs,
whereas faces contain mainly DCA, LCA, along with
minor amounts of CDCA, CA and UDCA ,and a variety of
bacteria transformed derivatives (Ridlon et al. 2006).
Several bacterial species in the genus Clostridium have
been isolated and confirmed to convert primary bile acids
into secondary bile acids, a process termed bile acids
7a-dehydroxylation. There previously proposed a multistep
biochemical pathway for bile acids 7a-dehydroxylation.
The current model of bile acid 7a-dehydroxylation sug-
gests that free primary bile acids are actively transported
into the bacterial cell by a proton-dependent bile acids
transporter encoded by the baiG gene (Mallonee and
Hylemon 1996). Once inside, the primary bile acids is
ligated to an ATP-dependent CoA, adjusted by the baiB
gene product (Mallonee et al. 1992). The baiA gene encodes
3a-HSDH, which is specific for primary bile acid CoA
conjugates (Mallonee et al. 1995). It is recently reported
that the baiCD and baiH gene products encode stereospe-
cific 3-dehydro-4-bile acid oxidoreductases, which can rec-
ognize 7a-hydroxy bile acids (CA, CDCA) and 7b-hydroxy
bile acids [UDCA, 3a,7a-dihydro-5b-cholan-24-oic acid],
respectively (Kang et al. 2008). The rate-limiting and irre-
versible step in this pathway is 7a-dehydration that cata-
lyzed by bile acid 7a-dehydratase, which is encoded by the
baiE gene (Dawson et al. 1996). The 3-dehydro-4,6-bile
acid intermediate is then sequentially reduced and exported
from the cell. However, genes in the ‘‘reductive arm’’ of the
pathway have yet to be identified. Previously, the baiF gene
product hydrolyzes bile acid CoA conjugates (Ye et al.
1999). Moreover, the product of gene based on amino acid
sequence comparisons may be a bile acid CoA transferase.
Further, there exists strong evidence that the baiF gene
encodes a bile acid CoA transferase with broad bile acid
substrate specificity (Heider 2001). In a word, the discovery
and characterization demonstrate that bile acid 7a-dehydr-
oxylation is a multistep pathway and suggest the presence
of multiple bai genes.
Bile Acid Synthesis, Transporters, and Regulatory
Nuclear Receptors in the Enterohepatic Circulation
Bile acid (BA) transporters are indispensable for main-
taining the enterohepatic circulation of bile acids. Main-
tenance of the enterohepatic BAs circulation is vital for
several liver and gastrointestinal functions including bile
flow, solubilization and excretion of cholesterol, clearance
of toxic molecules, intestinal absorption of lipophilic
nutrients, as well as metabolic and antimicrobial effects
(Hofmann 2007). In the body, BAs are actively taken up
from the lumen of the terminal ileum efficiently, which is
carried in by the apical sodium-dependent BA transporter
(ASBT, gene symbol SLC10A2), meanwhile leaving only
approximately 5 % (or approximately 0.5 g/d) in the lumen
(Dietschy and Turley 2002). In contrast, this fraction is in
part passively absorbed in the colon, a process facilitated
by bacterial transformation (see above), and the others
extruded with faces.
Bile acids homeostasis in the enterohepatic circulation is
controlled by genes of nuclear receptors (NRs). Except
NRs as intracellular BA sensors, some cells also contain
BA receptors at the cell surface including a G-protein-
coupled receptor (TGR5/M-BAR/GPBAR1) (Maruyama
et al. 2002) and the epidermal growth factor receptor (Rao
et al. 2002). Under physiological conditions, these regu-
latory networks preserve the enterohepatic BAs circulation
and limit intracellular levels of potentially toxic BAs.
Hence it is necessary to maintain proper BAs homeostasis
regulated by transporters via NRs. Furthermore, hereditary
and acquired defects of BA transporters are involved in the
pathogenesis of several hepatobiliary disorders such as
cholestasis and gallstones.
The Enterohepatic Circulation of Bile Acid
Bile Acid Synthesis in Liver
Bile acids are synthesized from cholesterol by either a
classical pathway or an alternative pathway resulting in
formation of CA or chenodeoxycholic acid (CDCA). In the
classical pathway, the cholesterol undergoes a series of
hydroxylations catalyzed by cytochrome P450 enzyme
CYP7A1, CYP8B1 (Eggertsen et al. 1996), and CYP27
(Cali and Russell 1991). In the alternative pathway,
7a-hydroxylation is preceded by the formation of several
different oxysterols. Oxysterols is hydroxylated by
CYP7B1 and CYP39A1 (Li-Hawkins 2000; Schwarz
1997). Moreover oxysterols are also substrates of CYP7A1
(Norlin et al. 2000) and 7a-hydroxylation of oxysterols
blocks their ability to inhibit sterol regulatory element-
binding protein (SREBP) (Schroepfer 2000). Thus,
7a-hydroxylation of oxysterols can markedly influence
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lipid metabolism through increasing the expression of
genes normally regulated by SREBP. Meanwhile the low-
density lipoprotein receptor (LDLR) (Dueland 1992) also
regulates the expression of SREBP-regulated genes.
Hepatocellular Bile Salt Excretion Canalicular Export
Systems
At the canalicular membrane, highly specialized canalicu-
lar transporters mediate excretion of the individual com-
ponents of bile such as BAs, phospholipids, and cholesterol
(Trauner 2003). The bile salt export pump (nomenclature
BSEP, ABCB11 or sister of p-glycoprotein (Spgp)) is the
major canalicular BAs efflux system (Gerloff et al. 1998).
Importantly, the existence of other transporters is proved
by Makishima (1999) and Stieger et al. (2011) by means of
BSEP konckout mouse. BSEP expression and activity are
tightly controlled at transcriptional and post-transcriptional
levels. Farnesoid X receptor (FXR) upregulates BSEP
expression (recently reviewed in Stieger 2011), while
BSEP is downregulated by inflammatory, injury, and
estrogen, for example obstructive cholestasis (Wagner
et al. 2010). The canalicular membrane also contains
transport systems mediating excretion of biliary phospho-
lipids (nomenclature MDR3, MDR2 in rodents or ABCB4)
and cholesterol (ABCG5/8), which are tightly coupled with
BAs excretion (Lo et al. 2008). Another ABC transporter
involved in cholesterol transport is ATP-binding cassette,
sub-family A 1 (ABCA1), which mediates cellular cho-
lesterol efflux from peripheral macrophages but also
expressed at the basolateral surface of hepatocytes and
Caco2 cells (Ohama et al. 2002; Neufeld et al. 2002). There
are other canalicular transport systems that are less
important for BAs transport. For instance multidrug resis-
tance-associated protein 2 (MRP2/ABCC2) mainly
excretes bilirubin–glucuronides and glutathione conju-
gates, but also transports divalent sulfo-conjugated BAs
into the bile.
Alternative Basolateral Efflux Systems in Hepatocytes
When hepatocellular BAs overload, BAs can also be
transported back to the sinusoidal blood to protect the liver
and then undergo elimination through the urine. To provide
less toxic and higher affinity substrates for the basolateral
BAs export systems, BAs is associated with phase I and II
detoxification (Zollner 2006). Basolateral efflux systems
contain the multidrug resistance-associated proteins MRP3
(ABCC3), MRP4 (ABCC4), and the heterodimeric organic
solute transporter (OSTa/OSTb). Analyses of the role of
MRP3 in liver with respect to endobiotics have focused on
glucuronides and monoanionic bile acids, which are well-
established transport substrates of the pump. MRP3 mice
made cholestatic by bile duct ligation have lower serum
levels of bilirubin glucuronide, a conjugate formed in the
liver, compared to cholestatic wildtype mice.
Cholangiocytes and Bile Acid Transport
Bile duct epithelial cells (cholangiocytes) are important
modifiers of bile formation by promoting bicarbonate
excretion and the bile ducts act as drainage system for BAs
flowing to the intestine. After hepatocytes secrete bile salts
into the bile canaliculus, primary hepatic bile acids are
modified during its passage through the biliary tree by
organic anion and electrolyte transport proteins expressed
in biliary epithelial cells. In contrast, conjugated BAs
require active transport into cholangiocytes via an apical
sodium-dependent BA transporter (ASBT/SLC10A2),
which is identical to the transport system in the ileum (see
below) (Lazaridis et al. 1997). BAs are exported into the
adjacent peribiliary capillary plexus via OSTa/b, MRP3,
and possibly a truncated version of ASBT (tABST)
(recently reviewed in (Claudel et al. 2011)). The physio-
logical role of bile salts uptake by cholangiocytes probably
pertains to the regulatory effect of bile salts on intracellular
signaling mechanisms including cholangiocellular mucin
and bicarbonate secretion (Hirata 2001; Jungst and
Sreejayan 2007).
Intestinal Bile Acid Transporters
BAs are mainly actively taken up in the terminal ileum via
ASBT, apart from a relatively small proportion of passive
uptake in the proximal small intestine and colon (Shneider
2001; Dawson et al. 2003). Interestingly, enterocytes,
cholangiocytes, and renal tubular cells share several BA
transport systems including ASBT (see above) (Zollner
2006). After reabsorption, BAs are bound to the cytosolic
ileal BA binding protein IBABP (also known as ileal lipid
binding protein (ILBP) and fatty acid binding protein 6,
FABP6) and exported into the portal blood via OSTa/
OSTb (Dawson et al. 2009). Bile acids escape ileal reab-
sorption and are transformed by intestinal flora in the
colon, where the secondary BAs take up through efflux
systems (e.g., OSTa/OSTb) (Zollner 2006).
Hepatocellular Uptake of Bile Salts
The final step in the enterohepatic circulation of bile salts is
the extraction from portal blood plasma by hepatocytes,
whereas a much lesser amount from the hepatic artery, and
are efficiently removed during their first passage through
the hepatic sinusoids by hepatocellular BA uptake systems
(Kullak-Ublick et al. 2004), involving a sodium-dependent
sodium/taurocholate co-transporting polypeptide (NTCP/
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SLC10A1) and a family of sodium-independent multi-
specific organic anion transporters (OATPs/SLCOs) (Ku-
llak-Ublick et al. 1994; Hagenbuch 1994). This process is
described in detail in several recent review articles (Trau-
ner 2003). Bile salts circulate in plasma are tightly bound
to albumin and lipoproteins such as high-density lipopro-
tein (Wolkoff and Cohen 2003). NTCP accounts for the
bulk (about 90 %) of BA uptake and is the first cloned BA
transporter (Hagenbuch 1994). Its regulation under physi-
ological and pathological conditions is therefore well
understood thus serving as a paradigmatic model to
understand transporter regulation. NTCP expression is
controlled by BAs, hormones such as estrogen and pro-
lactin, as well as pro-inflammatory cytokines (recently
reviewed in Wagner et al. 2010).
Next to the sodium-dependent uptake system NTCP, the
organic anion transporting polypeptides 1B1 (OATP1B1,
encoded by the SLCO1B1 gene), OATP1B3 (SLCO1B3),
and OATP2B1 (SLCO2B1) are major uptake transporters
on the sinusoidal membrane of human hepatocytes. They
mediate the influx of endogenous compounds such as bile
salts, bilirubin glucuronides, thyroid hormones and steroid
hormone metabolites, and clinically frequently used drugs
like statins, HIV protease inhibitors, and the anti-cancer
agents irinotecan or methotrexate (Hagenbuch 2004; Gia-
comini et al. 2010; Niemi 2011; Nies et al. 2008).
Transcriptional Regulation of Bile Salt Transporters
Expression of bile salt transporters in enterohepatic circulation
determines not only uptake and efflux systems but also key
bile acid synthetic enzymes. To ensure the balance between
synthesis, uptake and excretion, expression of bile salt trans-
porters is tightly regulated by NRs. NRs provide a network of
negative feedback and positive feed-forward mechanisms, in
order to control intracellular concentration of biliary constit-
uents, which are often also ligands for these NRs.
Liver X Receptor
Liver X receptors (LXRs) were initially characterized as
sterol sensors that affect cholesterol and lipid homeostasis
and inflammation (Tontonoz 2003). In rodents, LXRa pro-
motes bile acid synthesis by activating cytochrome P450
7A1 (Cyp7a1), a rate-limiting enzyme, to convert cholesterol
to bile acids (Peet et al. 1998; Chiang 2004). It showed that
LXR can also promote bile acid detoxification and alleviate
cholestasis. LXRs are known to induce the expression of
cholesterol and phospholipid efflux transporters. These
include the canalicular cholesterol efflux transporters
ABCG5 and ABCG8 (Repa et al. 2002), as well as ABCA1, a
basolateral ABC transporter that effluxes both cholesterol
and phospholipids (Chawla 2001; Groen et al. 2001;
Mulligan et al. 2003). The potential effects of LXR on the
homeostasis of bile acid, cholesterol, and phospholipids
may play a role in the pathogenesis of cholesterol gall-
stone disease (CGD). LXR-mediated increases in the biliary
efflux of cholesterol and phospholipids as well as a reduced
biliary bile salt pool size, resulting from sensitizing mice of
lithogenic diet, induced gallbladder cholesterol crystalliza-
tion (Uppal et al. 2008).
Role of the Farnesoid X Receptor (FXR) in Controlling
Bile Acid Homeostasis
FXR has a predominant role in regulating bile acid synthesis
and bile salt transport. A rise in intracellular bile acid levels
results in an increase in binding of bile acids to the ligand-
binding domain of FXR and in transcriptional activation of
its target genes. One such hepatic FXR target gene is the
small heterodimer partner (SHP; NR0B2) (Goodwin 2000),
an atypical member of the NR superfamily that lacks a
DNA-binding domain (Seol 1996). SHP can dimerize with
and inactivate both LRH1 and LXRa, resulting in a decrease
in Cyp7a1 expression (Goodwin 2000; Brendel and
Schoonjans 2002). Support for this model comes from
studies showing that treatment of SHP impaired mice with a
potent, synthetic FXR agonist (GW4064) fails to repress
Cyp7a1 mRNA levels (Kerr et al. 2002).
Another pathway that regulates bile acid production is
initiated after activation of FXR in enterocytes; this acti-
vation is induced through enhancing transcription and
secretion of fibroblast growth factor 15 (FGF15). Sub-
sequent binding of FGF15 to fibroblast growth factor
receptor 4 (FGFR4), a transmembrane tyrosine kinase
receptor localized on the hepatocyte cell surface, results in
activation of the c-Jun N-terminal kinase (JNK) pathway
and repression of Cyp7a1 and Cyp8b1 (Inagaki et al.
2005). A prove for the importance of FGF15 in this path-
way came from the earlier observation that both Cyp7a1
expression and the bile acid pool are increased in FGFR4-
lacking mice (Yu et al. 2000).
In addition to Cyp7a1 and Cyp8b1, FXR also regulates
genes involved in bile acid (e.g., BSEP, MRP2) and
phospholipid (e.g., human MDR3 or mouse Mdr2) secre-
tion across the bile canalicular membrane, bile acid trans-
port (ASBT, NTCP, IBABP, OSTa–OSTb), and bile acid
conjugation and detoxification (e.g., SULT2A1, UGT2B4,
BACS, BAT) (Lee et al. 2006).These findings suggest that
FXR is the primary bile acid sensor that coordinately
regulates bile acid metabolism.
Pregnane X Receptor (PXR) in Bile Acid Metabolism
PXR regulates both the basal expression and repression of
Cyp7a (Staudinger et al. 2001a; 2001b). Interestingly, PXR
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does not regulate Shp expression. Thus, PXR represses
Cyp7a1 through a mechanism distinct from that of FXR. In
addition to Cyp7a1, PXR also regulates other genes that
have also been implicated in bile acid metabolism. These
genes include MRP2 (Kast et al. 2002) and OATP2
(Staudinger et al. 2001b), which transport bile acids across
hepatic canalicular and sinusoidal membranes, respectively
(48); and, CYP3A, which hydroxylates bile acids including
lithocholic acid (LCA) (Araya and Wikvall 1999). Unlike
FXR, PXR is not activated efficiently by CA, chenodeox-
ycholic acid, or their conjugated derivatives. However,
both the mouse and human PXR are activated efficiently by
the secondary bile acid LCA and its 3-keto metabolite
(Staudinger et al. 2001; Xie et al. 2001).
Role of Other Transcription Factor (VDR, CAR, PPARa,
GR) in the Regulation of Bile Salt
The basolateral bile salt transporter Mrp3, which is
strongly induced in obstructive cholestasis in rats and
compensates for decreased Mrp2 expression, is induced by
constitutive androstane receptor (CAR) (Soroka et al.
2001). CAR is a NR known to strongly activate CYP2B1
expression, and recent evidence suggests that bilirubin may
induce translocation of CAR from the cytosol to the
nucleus, suggesting a regulatory role of CAR in cholestatic
liver disease (Cherrington et al. 2002; Xiong and Yoshinari
2002).
Vitamin D receptor (VDR) binds 1a,25-(OH)2-vitamin
D3 with high affinity and mediates classic calcitriol effects
such as regulation of calcium and phosphate homeostasis.
Krasowski et al. (2011, 2008) suggest that only VDRs from
animals that predominantly use 5b-bile acids are activated
by bile acids, possibly as an adaptive response to limit the
toxicity of secondary bile acids generated in the intestinal
tract.
The apical sodium-dependent bile salt transporter ASBT
and the hepatocyte canalicular phospholipid flippase Mdr2/
MDR3 (ABCB4) are activated by PPARa (Jung and Fried
2002; Kok 2003). A key function of PPARa is the regu-
lation of genes involved in various steps of fatty acid
metabolism (Desvergne and Wahli 1999) and PPARa
ligands include fatty acids and fibrate drugs. Fibrate drugs
are ligands of PPARa and an important adverse effect of
fibrate treatment is the increased risk of cholesterol gall-
stone formation (see below).
The glucocorticoid receptor (GR) is a nuclear steroid
hormone receptor that is activated by nanomolar concen-
trations of glucocorticoids. The human ASBT gene has
been proved to be transactivated by the GR and an
induction of ASBT by glucocorticoids could be beneficial
in patients with Crohn’s disease who exhibit reduced
ASBT expression (Jung 2004). The NTCP promoter is
activated by GR in a ligand-dependent manner, similarly to
the ASBT promoter. Thus, glucocorticoids may coordi-
nately regulate the major bile acid uptake systems in
human liver and intestine, while providing a negative
feedback mechanism for bile acid uptake in human
hepatocytes.
Enterohepatic Circulation and Gallstone
In theory, each factor that disequilibrates the enterohepatic
circulation will lead to the formation of gallstones. None-
theless, there still remain many unknown aspects when it
comes to regulation of the bile acid homeostasis in the
enterohepatic circulation. In the past few decades, it’s
widely accepted that the most important prerequisites for
gallstone formation are hypersecretion of biliary choles-
terol and cholesterol supersaturation of the bile. Mean-
while, gallstone also exhibits abnormality of bile acid,
reduction of gallbladder motility, prolongation of intestinal
transit time. In the following, we will expose the cause of
gallstones in detail.
Role of Bacteria in Gallstone Disease
Secondary bile acids are synthesized in the human colon
from the bacterial 7alpha-dehydroxylation of primary bile
acids. Increased levels of secondary bile acids have been
correlated with an increased risk of CGD. Moreover,
increased CA-7alpha-dehydroxylation activity of the
intestinal microflora may be an important factor for cho-
lesterol gallstone formation or growth in gallstone patients.
High levels of CA 7a-dehydroxylating fecal bacteria have
been correlated with increased amounts of DCA in bile of a
subset of cholesterol gallstone patients. Treatment of these
cholesterol gallstone patients (high DCA group) with
antibiotics significantly decreased the levels of fecal CA
7a-dehydroxylating bacteria, DCA in bile, and the choles-
terol saturation index in bile (Berr 1996). The optimal
reaction conditions of cholylglycine hydrolase and 7a-de-
hydroxylase are measured in fresh caecal samples, obtained
by aspiration during clinically-indicated colonoscopy. This
is an essential first step to further studies of intestinal
bacterial enzymes in the pathogenesis of CGD (Thomas
et al. 1997). UDCA, which can be used as an therapeutic
agent for the non-surgical dissolution of gallstones as well
as for the treatment of primary sclerosing cholangitis and
primary biliary cirrhosis (Beuers et al. 1992). The key
enzymatic steps in the synthesis of UDCA are the reduction
of dehydrocholic acid (DHCA) to 12-keto-ursodeoxycholic
acid. Recently, it is observed that 7b-hydroxysteroid
dehydrogenase (7b-HSDH) from Collinsella aerofaciens,
3a-hydroxysteroid dehydrogenase (3a-HSDH) from
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Comamonas testosteroni with glucose dehydroge-
nase(GDH) from Bacillus subtilis for cofactor regenera-
tion, which was able to completely convert 100 mM
DHCA to [99.5 mM 12-keto-UDCA within 4.5 h in a
simple batch process on a liter scale (Sun et al. 2013).
Acromegalic patients have slow colonic transit,
increased rates of deoxycholic acid formation, and an
increased prevalence of cholesterol gall stones, especially
during long-term octreotide treatment. The increasing de-
oxycholic acid formation seen in acromegalics during
octreotide treatment is due not only to the greater numbers
of facal anaerobes but also to increased activity of the rate-
limiting enzyme pathway (7alpha-dehydroxylation) con-
verting cholic acid to deoxycholic acid (Thomas et al.
2005). It is found that gallstone patients had [42-fold
(p \ 0.01) higher levels of 7alpha-dehydroxylating bacte-
ria than patients who had not developed gallstones. And all
strains of 7alpha-dehydroxylating bacteria isolated from
gallstone patients appear to belong to the genus Clostrid-
ium (Wells et al. 2000). Moreover, antibiotic treatment
decreases facal 7a-dehydroxylation activity, and lowers
biliary deoxycholate and cholesterol concentration (Berr
1996).
Bacterial DNA sequences are usually present in mixed
cholesterol (to 95 % cholesterol content), brown pigment,
and common bile duct, but rarely in pure cholesterol
gallstones (Lee et al. 1999). Stewart and co-authors (2007,
2007) have readily cultured bacteria from cholesterol
stones with pigment centers. Bacteria sequestered in cho-
lesterol stones cause fewer infectious than pigment stone
bacteria. Possibly because of their isolation, cholesterol
stone bacteria were less often present in bile and blood,
induced less immunoglobulin G, were less often killed by a
patient’s serum. Bacteria-laden gallstones are biofilms
whose characteristics influence illness severity. Factors
(beta-glucuronidase/phospholipase) creating colonization
surface facilitated bacteremia and severe infections. But at
the same time, abundant slime production not only facili-
tates colonization, but also inhibits detachment and cho-
langiovenous reflux. What is more, germ-free rederivation
rendered mice more susceptible to cholesterol gallstone
formation. This susceptibility appeared to be largely due to
alterations in gallbladder size and gallbladder wall
inflammation (Fremont-Rahl et al. 2013).
Role of Intestine in Gallstone Disease
In gallstone patients, both small intestinal and whole gut
transit times are prolonged compared to normal controls.
Therefore, we can conjecture that impaired intestinal
motility might promote gallstone formation. One possible
link between impaired intestinal motility and lithogenic
bile could be secondary hydrophobic bile salt
deoxycholate. We can find the evidence from studies in
humans and mice. For example, it is reported that gallstone
patients have longer large bowel transit times, more total
and gram-positive anaerobes and more 7a-dehydroxylating
activity in the caecum than normal subjects (Thomas et al.
2000). Further, treatment with octreotide that is known for
the risk factor of CGD, which not only increases biliary
deoxycholate concentration but also prolongs colonic
transit time (Thomas et al. 2005).
It is also believed that ileal disease, bypass, or resection
represent a major risk factor for gallstones, according to
study on prairie dogs that underwent ileal resection or
Crohn’s disease, whose cholesterol saturation indexes of
gallbladder bile remained essentially unchanged, whereas
pigment gallstones formed frequently (Jung 2004; Pitt et al.
1984). The role of chronic intestinal infection as a potential
factor in cholesterol gallstone pathogenesis has been pro-
posed. Distal intestinal infection with a variety of enter-
ohepatic Helicobacter species, but not Helicobacter pylori,
are essential to nucleate cholesterol supersaturated bile in a
well-established murine model of cholesterol gallstone
formation (Maurer et al. 2006; Maurer et al. 2005). Bile
salt malabsorption is another factor of gallstone. For
example, excess dietary carbohydrates are known to cause
bile salt malabsorption. Bile salt malabsorption has been
induced in mice and hamsters by a diet rich in nondigest-
ible starch and b-cyclodextrin (Abadie et al. 1994). Similar
results have been found with diets replete in refined sugars:
high sucrose diets increase fecal bile salt loss, possibly
because of induction of more rapid intestinal transit (Kruis
et al. 1991). Meanwhile, chronic alcohol ingestion by
laboratory animals leads to bile salt malabsorption due to
morphological and functional alterations of the small
intestinal mucosa, which may compromise Na? -coupled
bile salt transport (Zucoloto and Muccilo 1985). Recent
experimental studies on mice with defects in the cystic
fibrosis transmembrane conductance regulator gene
(CFTR) have shown that bile salt malabsorption also
occurs in these animal models, which may be caused by the
disorder of mucin, and leads to gallstone (Debray et al.
2012). Moreover, prolonged TPN may also cause ileal
atrophy and downregulation of ileal ASBT, complicating
the scenario with added bile salt malabsorption (Matsum-
ura et al. 1993).
Role of Gallbladder in Gallstone Disease
Impaired postprandial gallbladder emptying, often present
in cholesterol gallstone patients, may prolong residence of
bile in the gallbladder, thus allowing more time for
nucleation of cholesterol crystals from supersaturated bile
and their growth/aggregation into macroscopic stones.
Although impaired motility is generally secondary to
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biliary cholesterol supersaturation, it may still facilitate the
process of gallstone formation. Gallbladder motility is
often impaired in many high-risk situations for gallstone
formation, such as pregnancy, obesity and rapid weight loss
in obese patients, diabetes mellitus, and total parenteral
nutrition (van Erpecum et al. 2000). Meal-induced release
of cholecystokinin (CCK) from the duodenum is the prin-
cipal factor driving gallbladder smooth muscle contraction,
accounting for 70–80 % of the decrease of fasting gall-
bladder volume. The CCK-1-receptors-deficient mice have
larger gallbladder volumes (predisposing to bile stasis),
significant retardation of small intestinal transit times
(resulting in increased cholesterol absorption), and
increased biliary cholesterol secretion rates. And the mice
result in a significantly higher prevalence of cholesterol
gallstones for the absence of CCK-induced contraction
(Wang et al. 2004). A primary role for gallbladder motility
in gallstone formation is also indirectly supported by the
observation that daily CCK injection during total parenteral
nutrition or inclusion of dietary fat to enhance CCK release
during rapid weight loss restores gallbladder contractility
and can prevent gallstone formation (Gebhard et al. 1996;
Sitzmann et al. 1990).
Gallbladder wall inflammation may also be critical in
gallstone formation. The gallbladder wall is exposed to
detergent bile salts, unesterified cholesterol and bacteria,
which all could induce inflammation. The murine infected
with Helicobacter spp and fed a lithogenic diet develops
cholesterol gallstone at 80 % prevalence by 8 weeks
compared with approximately 10 % in uninfected controls.
This result indicates that Helicobacter spp play a signifi-
cant role in the pathophysiology of cholesterol gallstone
formation in mice and perhaps humans (Maurer et al.
2005). Subsequent studies confirm that T cells are critical
in murine cholesterol cholelithogenesis. Wild-type mice
develop significantly more cholesterol gallstones than
congenic immunodeficient Rag2(-/-) (Rag) mice. Mean-
while T lymphocytes to Rag2(-/-) mice increased stone
prevalence markedly (Maurer et al. 2007). Although vari-
ous helicobacter species have been detected in human
gallbladders and bile, and antibodies to helicobacter hep-
aticus were found at increased frequency in gallstone
patients, the role of helicobacter in human gallstone path-
ogenesis remains to be defined.
Role of Bile Acids Transporters in Gallstone Disease
Bile acids transporters play a important role in pathogen-
esis of gallstone. As it is known to us, enterocytes, cho-
langiocytes, and renal tubular cells all contain apical
sodium-dependent bile acid transporter (ASBT) which is
one of BAs transport systems. Interestingly, female who
are deficient of the ASBT and ILBP in the cholesterol, low
BAs or phospholipid concentrations, as well as BAs and
phospholipid species, deter small intestine result in pro-
moting gallstone formation (Bergheim et al. 2006). It
observes that an impaired function of OSTa–OSTb may
lead to low ileal bile acid reabsorption and an altered bile
acid pool composition and therefore may contribute to the
formation of gallstones in non-obese patients (Renner et al.
2008). A decreased expression of the ileal ASBT gene
SLC10A2 develops the formation of gallstone, and Com-
prehensive statistical analysis provides strong evidence that
allele of rs9514089 is a genetic determinant especially in
male non-obese gallstone carriers (Renner et al. 2009).
What is more, the decreased hepatic NPC1L1 levels may
leads to the cholesterol supersaturation because of the
malabsorption of biliary cholesterol in the liver in Chinese
female gallstone patients (Cui et al. 2010).
The process of nascent bile formation is maintained by
an elaborate network of ATP-binding cassette (ABC)
transporters in the hepatocyte canalicular membrane which
enable biliary secretion of cholesterol, bile salts, and
phospholipids. Higher hepatic messenger RNA expression
of ABCG5 and ABCG8 correlates positively with higher
biliary cholesterol levels (Yu 2002). The variants
ABCG8(D19H) are proved to be a susceptibility factor for
human gallstone disease via a genome-wide association
scan (Buch et al. 2007). Recently, mutation detection and
genotyping yield two chololithiasis-associated variants:
ABCG5-R50C and ABCG8-D19H. Moreover, the
ABCG8-19H variant has a high transport capacity, which
was also superior in nested logistic regression models in
German, Chilean, and Chinese patient samples (von
Kampen et al. 2013). Henkel and Wei (2005) observes that
overexpress BESP (ABCB11) in mice fed a lithogenic diet
have an increased rate of cholesterol crystal and gallstone
formation. This was associated with an increase in both the
hydrophobic bile salt and cholesterol content of gallbladder
bile. Analysing the entire MDR3 (ABCB4) gene coding
sequences represents that MDR3 (ABCB4) gene mutations
are a major genetic risk factor in a symptomatic and
recurring form of cholelithiasis in young adults (Rosmor-
duc and Hermelin 2003). Nevertheless, recent data from sib
pairs with gallstones and control do not support a link
between ABCB4 and ABCB11 polymorphisms and gall-
stone formation in the large majority of patients (Acalov-
schi et al. 2009).
The down-regulation of NTCP1 (SLC10A1) protein
expression might protect hepatocytes from high intracel-
lular bile salt loads in the lithogenic diet mice (Muller et al.
2002). Organic anion transport protein 1B1 (OATP1B1)
(encoded by SLCO1B1) is a major transporter protein for
bile salt uptake in enterohepatic circulation of bile salts.
The frequency CA genotype and A allele of Exon4 C [ A
polymorphism was higher in gallstones patients (12.4 and
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6.2 %) as compared to controls (5.2 and 2.6 %). These
results confirm the increasing risk of gallstone disease in
North Indian population (Srivastava et al. 2011).
Role of Nuclear Receptors in Gallstone Disease
FXR is a member of the NR superfamily and regulates
hepatic expression of BESP (ABCB11) and MDR3
(MDR2/ABCB4), thus affecting amounts of solibilizing
bile salts and phospholipids in bile. FXR deficient mice are
highly susceptible to gallstone formation, which treating
with a synthetic FXR agonist can prevent gallstone disease.
These results maybe relate to the low amounts of biliary
bile salts and phospholipids, which are regulated by BESP
and MDR3 (Moschetta 2004). What is more, research
suggests that FXR and the heterodimer ABCG5/ABCG8
are possible determinants of cholesterol gallstone forma-
tion in mice via quantitative trait locus analysis (Witten-
burg 2003). The loss of the ASBT and ILBP)in female
normal weight gallstone carriers is coupled with a reduc-
tion of protein levels of hepatic nuclear factor 1alpha and
FXR (Bergheim et al. 2006). The absence of b-Klotho
would be predicted to disrupt the FXR–FGF15/19-medi-
ated gut liver signaling, the most relevant pathway for
FXR-dependent CYP7A1 down-regulation (Franz et al.
2001), leading to increased CYP7A1 levels. Thus, inhibi-
tion of bKlotho could improve current (i.e., UDCA) and
potential future therapies (i.e., synthetic FXR agonists) for
gallstone disease by increasing cholesterol breakdown via
increasing CYP7A1, which is typically reduced in treat-
ment with FXR agonists.
We have illustrated that LXR regulates expression of
ABCG5/G8 cholesterol transport protein. The current study
has revealed a novel lithogenic role of LXR as well as a
functional interplay between LXR and LDLR in gallblad-
der cholesterol crystallization and possibly CGD in the
murine model. Furtherly, in a small group of Chinese non-
obese normolipidemic gallstone patients, the upregulation
of ABCG5/ABCG8 in gallstone patients is mediated by
increased LXRalpha possibly, may contribute to the cho-
lesterol supersaturation of bile and the formation of gall-
stone (Jiang et al. 2008). In addition, LXRb and PPARd
coordinate Niemann-Pick C1-like L1(NPC1L1/ABCA1)-
dependent vectorial cholesterol flux from bile through
cholangiocytes and manipulation of these processes may
influence bile composition in murine with gallstone (Xia
et al. 2012).
PXR knock-out mice associated with reduced expression
of cholesterol 7alpha-hydroxylase present a decrease in
biliary concentrations of bile salts and phospholipids and
an increase in the cholesterol saturation index and forma-
tion of cholesterol crystals (He et al. 2011). Fasted mice
with hepatocyte-specific GR knockdown have smaller
gallbladder BA content and are more susceptible to devel-
oping cholesterol gallstones when fed a cholesterol-rich diet.
Hepatic GR deficiency reduces the expression of the major
hepatocyte basolateral BA transporter, Na(?)-taurocholate
transport protein (NTCP/SLC10A1), which affected dietary
fat absorption and brown adipose tissue activation (Rose
et al. 2011). Role of VDR in BESP repression via direct
VDR–FXR interaction has been postulated in vitro. And
VDR is able to induce mouse MRP3 expression in intestine
(Honjo et al. 2006). CAR appears to play a central role in
regulating bile acid sulfation, since it is proposed to regulate
bile acid sulfation and subsequent basolateral export via
CAR-induced over-expression of the basolateral export
pump MRP4, which transports steroid sulfates (McCarthy
et al. 2005). But, there is not any direct research between
VDR or CAR and the formation of gallstone. Further
research is needed on the role of NRs in gallstone patho-
genesis and the therapeutic potential of the potent NR ago-
nists currently available. The review shows the latest
information as far as we know it, but there is still much work
remains to be done to identify the causal relation between
enterohepatic circulation and gallstone.
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